



ETCTN

Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network

National Cancer Institute at the
National Institutes of Health

Introduction

The National Cancer Institute (NCI) would like to know about your experiences with the Experimental Therapeutics Clinical Trials Network (ETCTN) over the past grant year (April 2014 - March 2015).

Your input will help NCI assess and refine the ETCTN processes and identify areas for improvement.

The survey will ask questions about ETCTN processes and activities and trial portfolio. It should take approximately **15** minutes to complete.


Your responses are confidential and all results will be reported in the aggregate. Your participation and responses will have no bearing on your ETCTN grant, or any future interactions with NCI.

We thank you for your assistance!

To continue and begin the survey, click the "Next" button below.

[Next >](#)



If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com



ETCTN

Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network

National Cancer Institute at the
National Institutes of Health

OMB# 0925-0046-09
Exp. Date: 05/31/2016

Privacy Statement and Consent

Collection of this information is authorized by The Public Health Service Act, Section 411 (42 USC 285a). Participation is voluntary and there are no penalties for not participating or withdrawing from the study at any time. The information collected in this study will be kept private to the extent provided by law. Names and other identifiers will not appear in any report of the study. Information provided will be combined for all study participants and reported as summaries. You are being contacted by User-Centered Design, Inc. via email to complete this instrument so that we can gain feedback from you on your experiences and recommendations regarding the implementation of the ETCTN program.

Please click the "Next" button if you consent to taking this survey.

Public reporting burden for this collection of information is estimated to average 15 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 208927974, ATTN: PRA (0925-0046-09). Do not return the completed form to this address.

[Next >](#)

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com




Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network

NIH National Cancer Institute at the National Institutes of Health

Opt-out of survey



Unsolicited Letter of Intent (LOI) Process for ETCTN Trials

*This set of questions asks you about your opinion of the **unsolicited** letter of intent (LOI) process.*

1. How aware are you of the **unsolicited LOI process** used in the ETCTN?

Not very aware

Very aware

2. How satisfied are you with the **unsolicited LOI process** in terms of ...

	Not very satisfied				Very satisfied	Don't know
Transparency of the unsolicited LOI submission process	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Transparency of the unsolicited LOI review process	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Efficiency of the unsolicited LOI process	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Communication received from NCI about the unsolicited LOI process	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Number of drugs available to investigators to develop quality LOIs	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Clarity of which drugs are available for unsolicited LOIs	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>


2a. Please describe any changes NCI could make to increase your satisfaction with the unsolicited LOI process.

[< Back](#)

[Save and Continue >](#)



Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com



Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network

National Cancer Institute at the
National Institutes of Health

[Opt-out of survey](#)

15% Complete

3. In the past grant year of the ETCTN (April 2014 - March 2015), which of the following steps have you or others at your site participated in for **unsolicited LOIs**? (Select all that apply.)


	Submitted an unsolicited LOI	Had an unsolicited LOI approved	Submitted a protocol	Had a protocol reviewed	Activated a protocol
I have ...	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
A colleague of mine has ...	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

< Back
Save and Continue >

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.



If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com

Note: 3a appears conditionally, populated with any items selected for "I have..." in Q3.



Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network

National Cancer Institute at the
National Institutes of Health

[Opt-out of survey](#)

20% Complete

3a. What is your level of satisfaction for these phases of the unsolicited LOI process that you were involved with?

	Not very satisfied				Very satisfied
Submitted an unsolicited LOI	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
LOI review process	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Submitted a protocol	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Protocol review process	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Activated a protocol	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

< Back
Save and Continue >

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com



Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network

National Cancer Institute at the National Institutes of Health

[Opt-out of survey](#)



Project Team Member Applications and Drug Development Plan to Develop ETCTN Trials

This set of questions asks you about your opinion of the Drug Development Project Team Member Application DDP/ (PTMA) process used to submit LOIs and protocols.

4. How aware are you of the Drug Development PTMA process (DDP/PTMA) used in the ETCTN?

Not very aware

Very aware

5. How much do you agree or disagree with the following statements about the DDP/PTMA process?


The DDP/PTMA process ...	Strongly disagree	Disagree	Agree	Strongly agree	Don't know
streamlines the development of early phase trials.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
encourages multidisciplinary teams.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
is a fair process to develop early phase trials.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
has reduced my workload in comparison to other early phase trial processes.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Overall, I am satisfied with the DDP/PTMA process.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

[< Back](#)

[Save and Continue >](#)



Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com



Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network

National Cancer Institute at the
National Institutes of Health

Opt-out of survey

30% Complete

6. In the past grant year of the ETCTN (April 2014 - March 2015), which of the following steps have you or others at your site participated in for the DDP/PTMA process? (Select all that apply.)

	Submitted a Project Team Member Application (PTMA)	Participated in a Drug Development Plan	Been a Co-Leader for a Drug Development Plan	Submitted a letter of intent (LOI)	Submitted a protocol	Activated a protocol
I have ...	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Others at my site have ...	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

< Back
Save and Continue >

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com

Note: 6a and 6b appear conditionally; 6a is populated with any items selected for “I have...” in Q6. 6b appears if 6a appears.




Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network

  National Cancer Institute at the National Institutes of Health

[Opt-out of survey](#)



6a. What is your level of satisfaction for each phase of the DDP/PTMA process in which you were involved?

	Not very satisfied				Very satisfied
PTMA submission process	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Development of drug plan	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Co-leading drug development plan	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Letter of intent (LOI) submission	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Protocol submission	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Protocol activation	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>


6b. Please describe any changes NCI could make to increase your satisfaction with the DDP/PTMA process.

[< Back](#)



[Save and Continue >](#)


Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com


Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network



National Cancer Institute at the
National Institutes of Health

[Opt-out of survey](#)
 40% Complete

Opening ETCTN Trials

7. Looking at the list of ETCTN protocols activated during the program's first year, please indicate whether or not your site has opened each.


	Have Opened	In Process of Opening	Have Not Opened
Protocol 1	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Protocol 2	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Protocol 3	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
... Protocol n	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

< Back
Save and Continue >



Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.


If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com

Note: 7a appears conditionally if “have not opened” is selected for any protocol in Q7.


Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network



National Cancer Institute at the
National Institutes of Health

[Opt-out of survey](#)
 45% Complete

7a. For what reasons have you not opened available ETCTN trials?

< Back
Save and Continue >

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com



Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network



[Opt-out of survey](#)



8. Based on your experiences in the past grant year, how satisfied are you with the following aspects of opening an ETCTN trial at your center?

	Not very satisfied				Very satisfied
Communication received about trial while it was in the pipeline	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Communication received from NCI during the process to open a trial	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Time required to open a trial	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Workload required to open a trial	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Time required to maintain a study	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Interactions with CTSU	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Interactions with CIRB	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Interactions with Theradex	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

8a. Please describe any changes NCI could make to increase your satisfaction with opening ETCTN trials at your site.

[< Back](#)

[Save and Continue >](#)

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com



Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network

National Cancer Institute at the National Institutes of Health

[Opt-out of survey](#)



ETCTN Trial Portfolio

9. ETCTN protocols are intended to be innovative and are not to be duplicative of research funded by industry or other resources.

Below is a list of ETCTN protocols that were activated during the past grant year. For each protocol, please indicate whether or not you consider the trial to be answering an important scientific question?

	Not important scientific question				Important scientific question	Don't know
Protocol 1	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Protocol 2	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Protocol 3	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
... Protocol n	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

10. Looking at the list of trials above, to what degree are you satisfied with the overall portfolio of activated protocols in the ETCTN?

Not satisfied

Very satisfied

[< Back](#)

[Save and Continue >](#)

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com



Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network



Opt-out of survey



11. Below is a list of considerations about the ETCTN portfolio.

Please indicate how satisfied you are with each topic with respect to the ETCTN portfolio of trials.

	Not satisfied				Very satisfied
Number of trials in portfolio	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Number of trials available for my center to open	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Representation of therapeutic classes	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Balance between scientific areas	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Lack of duplication with research conducted by industry or other sources	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Importance of scientific questions addressed	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Integration of preclinical findings	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

11a. Please describe any changes NCI could make to increase your satisfaction with the portfolio of trials.

[< Back](#)

[Save and Continue >](#)

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com



Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network

National Cancer Institute at the National Institutes of Health

[Opt-out of survey](#)



12. What changes would you like to see in the emphasis of different scientific areas in trials in the ETCTN portfolio?

	Less emphasis	About the same emphasis	More emphasis
Angiogenesis	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Immunotherapy	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Molecular characterizations of tumor features	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Organ dysfunction	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Organ dysfunction	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmacokinetics	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Signal transduction	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

12a. If other, please describe:

[< Back](#)

[Save and Continue >](#)

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com



Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network

NIH National Cancer Institute at the National Institutes of Health

[Opt-out of survey](#)



Network Readiness and Satisfaction with the ETCTN

13. Overall, how ready do you believe each of the groups below were to participate in the ETCTN at the beginning of the grant year in April 2014?

	Not ready				Very read	Don't know
Your center	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
The ETCTN overall	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

14. Overall, how ready do you believe each of the groups below is now to participate in the ETCTN?

	Not ready				Very read	Don't know
Your center	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
The ETCTN overall	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

[< Back](#)

[Save and Continue >](#)

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com



Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network



[Opt-out of survey](#)

75% Complete

15. Please review the statements below and indicate how much you agree or disagree with each.

	Strongly disagree				Strongly agree
There are enough trials activated in the ETCTN to reach our center's accrual goals.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Overall I am satisfied with the progress made over the ETCTN's first year.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
I expect most concerns that I have with the ETCTN in the first year will get worked out in the remaining years of the grant.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
There is strong collaboration among the different centers in the ETCTN.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
The collaboration with other centers in the ETCTN is productive.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
My center has a team-based approach for generating ideas for early phase trials.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Our center has made substantial changes to its processes to accommodate the ETCTN.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
The ETCTN opens up career opportunities for junior investigators at our center.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Overall, the NCI leadership is responsive to the ETCTN grantees' needs and input.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

[< Back](#)

[Save and Continue >](#)

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com



Team Driven. Cancer Therapy Focused.

Experimental Therapeutics Clinical Trials Network

NCI National Cancer Institute at the National Institutes of Health

[Opt-out of survey](#)



16. Below is a list of potential benefits to be achieved via the ETCTN network.

Please indicate if you think that each of the potential benefits is:

- More likely to occur with *ETCTN trials*,
- More likely to occur with *other investigator-initiated trials at your center*
OR
- Equally likely to occur with *other investigator-initiated trials and with ETCTN trials*


	More Likely to Occur With ETCTN Trials at my Center	More Likely to Occur With Other Investigator-Initiated Trials at my Center	Likely to Occur Equally With Other Investigator-Initiated Trials AND ETCTN Trials
Obtain IRB approval quickly.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Activate trials quickly at my center.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Participate in scientifically important trials.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Access drugs early in their development.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Participate in trials that will help advance my career.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Enroll patients to trials at the projected accrual rate.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Provide my patients access to a wide variety of early phase clinical trial options.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Collaborate with investigators at other centers.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Collaborate with researchers from other disciplines.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

[< Back](#)

[Save and Continue >](#)

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com



ETCTN

Experimental Therapeutics Clinical Trials Network

Team Driven. Cancer Therapy Focused.

NIH NCI National Cancer Institute at the National Institutes of Health

Opt-out of survey

85% Complete

Social Network Collaborations

We would like to learn more about your work with other researchers that are involved in the ETCTN.


17. Please look at the list of ETCTN organization members below and indicate a "yes" for those you had direct collaboration with over the past year (either developing protocols or opening trials).

ETCTN Lead Academic Organizations and Affiliates	Yes	No
Translational Genomics Research Institute	<input type="radio"/>	<input type="radio"/>
City of Hope Comprehensive Cancer Center	<input type="radio"/>	<input type="radio"/>
UC Davis Comprehensive Cancer Center	<input type="radio"/>	<input type="radio"/>
USC Norris Comprehensive Cancer Center	<input type="radio"/>	<input type="radio"/>
University of Colorado Cancer Center - Anschutz Cancer Pavilion	<input type="radio"/>	<input type="radio"/>
Yale Cancer Center	<input type="radio"/>	<input type="radio"/>
H. Lee Moffitt Cancer Center and Research Institute	<input type="radio"/>	<input type="radio"/>
Emory University/Winship Cancer Institute	<input type="radio"/>	<input type="radio"/>
University of Chicago	<input type="radio"/>	<input type="radio"/>
Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center	<input type="radio"/>	<input type="radio"/>
National Cancer Institute Developmental Therapeutics Clinic	<input type="radio"/>	<input type="radio"/>
University of Maryland Greenbaum Cancer Center	<input type="radio"/>	<input type="radio"/>
Dana-Farber Cancer Center	<input type="radio"/>	<input type="radio"/>
Massachusetts General Hospital	<input type="radio"/>	<input type="radio"/>
Wayne State University/Karmanos Cancer Institute	<input type="radio"/>	<input type="radio"/>
Mayo Clinic Rochester	<input type="radio"/>	<input type="radio"/>
Washington University	<input type="radio"/>	<input type="radio"/>
Rutgers University - Cancer Institute of New Jersey	<input type="radio"/>	<input type="radio"/>
Roswell Park Cancer Institute	<input type="radio"/>	<input type="radio"/>
Duke University	<input type="radio"/>	<input type="radio"/>
UNC Chapel Hill	<input type="radio"/>	<input type="radio"/>
Case Western Reserve University	<input type="radio"/>	<input type="radio"/>
Cleveland Clinic Foundation	<input type="radio"/>	<input type="radio"/>
Ohio State University Comprehensive Cancer Center	<input type="radio"/>	<input type="radio"/>
Fox Chase Cancer Center	<input type="radio"/>	<input type="radio"/>
University of Pittsburgh Cancer Institute	<input type="radio"/>	<input type="radio"/>
Vanderbilt-Ingram Cancer Center	<input type="radio"/>	<input type="radio"/>
University of Texas MD Anderson Cancer Center	<input type="radio"/>	<input type="radio"/>
Virginia Commonwealth University	<input type="radio"/>	<input type="radio"/>
University Wisconsin Carbone Cancer Center	<input type="radio"/>	<input type="radio"/>
British Columbia Cancer Agency	<input type="radio"/>	<input type="radio"/>
Juravinski Cancer Center	<input type="radio"/>	<input type="radio"/>
University Health Network/Princess Margaret Cancer Center	<input type="radio"/>	<input type="radio"/>

< Back
Save and Continue >

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.


If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com



ETCTN

Experimental Therapeutics Clinical Trials Network

Team Driven. Cancer Therapy Focused.



National Cancer Institute at the
National Institutes of Health

Opt-out of survey

90% Complete

Demographics

The next set of questions asks about your background and experience with cancer research.

18. Please indicate your sex:

Female

Male

19. Please indicate your ethnicity:

Hispanic or Latino

Not Hispanic or Latino

20. Please indicate your race (mark one or more of the following):

American Indian or Alaska Native

Asian

Black or African American

Native Hawaiian or Other Pacific Islander

White

21. Please indicate your scientific specialty?

22. How long have you been involved with ...

	1-5 years	6-10 years	11-15 years	16-20 years	20+ years
Early phase clinical trials	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Cancer research	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Your center	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

23. Other than NCI, where have you received funding for cancer research? (Select all that apply.)

Pharmaceutical industry

Pharmaceutical industry

Biotechnology companies

Department of Veteran Affairs


Department of Defense

< Back

Save and Continue >

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com



ETCTN

Experimental Therapeutics Clinical Trials Network

Team Driven. Cancer Therapy Focused.

NIH National Cancer Institute at the National Institutes of Health


Opt-out of survey
95% Complete

24. Do you have any final comments about ETCTN that you would like to share?

[< Back](#) [Submit Survey >](#)

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com



ETCTN

Experimental Therapeutics Clinical Trials Network

Team Driven. Cancer Therapy Focused.

NIH National Cancer Institute at the National Institutes of Health

Opt-out of survey
100% Complete

Thank you for completing this survey!

Your answers have been submitted securely.

We appreciate your feedback regarding the ETCTN.
Your feedback will help us refine the ETCTN and identify areas for improvement.

If you would like a summary of the findings after the survey closes,
please send an email to JenniferHuang@westat.com

You may now close this window.

Your information will be saved every time you hit "save and continue". You may close and return to this survey anytime until it is submitted.

If you experience any technical difficulties, please contact the survey administrator, User-Centered Design at survey@user-centereddesign.com